États-Unis · Plateformes & données · MarketBeat

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

Publié par MarketBeat · États-Unis il y a 1 h

WAVE Life Sciences (NASDAQ:WVE) outlined progress across its obesity-focused siRNA program and RNA editing pipeline during a Chardan discussion, with President and CEO Paul Bolno…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

À lire aussi

My father-in-law, 81, sold his $75,000 home and paid off his daughter’s $50,000 debt. What happens to him now?

Tesla Asian supplier shares fall after mixed Q3 earnings, cautious outlook

IBM Stock Heads For Best Week Since June: CEO Says ‘Q2 Softness Was Timing Rather Than Demand’ After Q3 Beat, Sees Infrastructure Momentum

How Investors Are Reacting To Aya Gold & Silver Stock After Boumadine PEA Update

KFC rolls out 13 days of Halloween deals, but there’s a catch

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

Partager

À lire aussi

My father-in-law, 81, sold his $75,000 home and paid off his daughter’s $50,000 debt. What happens to him now?

Tesla Asian supplier shares fall after mixed Q3 earnings, cautious outlook

IBM Stock Heads For Best Week Since June: CEO Says ‘Q2 Softness Was Timing Rather Than Demand’ After Q3 Beat, Sees Infrastructure Momentum

How Investors Are Reacting To Aya Gold & Silver Stock After Boumadine PEA Update

KFC rolls out 13 days of Halloween deals, but there’s a catch

Goldman Sachs, JPMorgan and Morgan Stanley are dominating the AI stock boom. Here's their edge